Could Targeting HMGB1 be useful for the Clinical Management of COVID-19 Infection?

Could Targeting HMGB1 be useful for the Clinical Management of COVID-19 Infection? Comb Chem High Throughput Screen. 2020 Jul 27;: Authors: Çelebier M, Haznedaroğlu İC Abstract Since the high mobility group box-1 (HMGB1) molecule had been recognized as a pro-inflammatory cytokine, which mediates endotoxin lethality of mice; there have been lots of papers about targeting the HMGB1 within the contexts of infection, inflammation, and cancer. The pathogenic impact of HMGB1 to the severe acute respiratory syndrome (SARS) and disease management with herbal formulations targeting this unique protein have already been proposed. However, the failure of the numerous current anti-viral therapies on the ongoing viral infections casts reappraisal of the possible interrelationships regarding the HMGB1 and SARS-CoV-2. COVID-19 pandemic due to the SARS-CoV-2 virus is a currently ongoing challenging global health crisis. There is still not any proved exact treatment of COVID-19 with high level of evidence. In this paper, we focused on the potential usage of external and/or inhalation preparation of antiviral/antibacterial herbal products capable of targeting HMGB1 for the clinical management candidates of the ongoing COVID-19 infection. PMID: 32723229 [PubMed - as supplied by publisher]
Source: Combinatorial Chemistry and High Throughput Screening - Category: Chemistry Authors: Tags: Comb Chem High Throughput Screen Source Type: research